J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
Eric Pujade-Lauraine,Jonathan A. Ledermann,Richard T. Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Andres Poveda,Sandro Pignata,Michael Friedlander,Nicoletta Colombo +9 more
Journal ArticleDOI
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Jonathan A. Ledermann,Hani Gabra,Gordon C Jayson,Victoria J. Spanswick,Gordon J. S. Rustin,Mark Jitlal,LE James,John A. Hartley +7 more
TL;DR: An enhanced activity of carboplatin in platinum-resistant ovarian cancer may be due to synergy with gem citabine through inhibition of repair of DNA cross-links following administration of gemcitabine.
Journal ArticleDOI
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
Paolo Pedrazzoli,Jonathan A. Ledermann,Jean Pierre Lotz,Serge Leyvraz,Massimo Aglietta,Giovanni Rosti,K. M. Champion,Simona Secondino,Frédéric Selle,N. Ketterer,Giovanni Grignani,Salvatore Siena,Taner Demirer +12 more
TL;DR: In this article, critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas.
Journal ArticleDOI
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
Jonathan A. Ledermann,Philipp Harter,Charlie Gourley,Michael Friedlander,Ignace Vergote,Gordon J. S. Rustin,Clare L. Scott,Werner Meier,Ronnie Shapira-Frommer,Tamar Safra,Daniela Matei,Anitra Fielding,Euan Macpherson,Brian Dougherty,Juliane M. Jürgensmeier,Maria Orr,Ursula A. Matulonis +16 more
TL;DR: A preplanned subgroup analysis from this randomized, double-blind Phase II trial suggested that olaparib may lead to a greater PFS, and an OS, benefit in pts with a known germline BRCAm (gBRCAm).
Journal ArticleDOI
Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.
Rob Glynne-Jones,Roger D James,Helen Meadows,Rubina Begum,David Cunningham,John M. A. Northover,Jonathan A. Ledermann,Sandra Beare,Latha Kadalayil,David Sebag-Montefiore +9 more
TL;DR: This investigation investigated the association between observation of CR at 3 different time-points and progression-free and overall survival (PFS, OS), to determine the optimal time to assess this early endpoint.